Pathological and molecular biological approaches to early mesothelioma

International Journal of Clinical Oncology

Volumn 17, Issue 1, 2012, Pages 40-47

  Tsujimura, Tohru ^a   Torii, Ikuko ^a   Sato, Ayuko ^a   Song, Misa ^a   Fukuoka, Kazuya ^a   Hasegawa, Seiki ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Atypical mesothelial proliferation; Mesothelioma; Mesothelioma in situ; p16 INK4a p14 ARF (CDKN2A); Reactive mesothelial hyperplasia

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MERLIN; BAP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

CANCER INVASION; CARCINOMA IN SITU; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL FEATURE; CYTOLOGY; DYSPNEA; EARLY CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; IMMUNOCYTOCHEMISTRY; MESOTHELIUM CELL; NEUROFIBROMATOSIS; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; THORAX PAIN; CANCER STAGING; EARLY DIAGNOSIS; GENETICS; MESOTHELIOMA; METABOLISM; PATHOLOGY; PLEURA TUMOR; TUMOR SUPPRESSOR GENE;

EARLY DETECTION OF CANCER; GENES, P16; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; NEUROFIBROMIN 2; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84862232824     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0369-1     Document Type: Review

References (69)

1. Robinson BWS, Chahinian AP (2002) Mesothelioma. Martin Dunitz Ltd, London
2. Robinson BW, Lake RA (2005) Advances in malignant meso-thelioma. N Engl J Med 353:1591-1603
3. Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29:2-17
4. Tsao AS, Wistuba I, Roth JA et al (2009) Malignant pleural mesothelioma. J Clin Oncol 27:2081-2090
5. Addis B, Roche H (2009) Problems in mesothelioma diagnosis. Histopathology 54:55-68
6. Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours, pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
7. Sugarbaker DJ, Mentzer SJ, Strauss G (1992) Extrapleural pneumonectomy in the treatment of malignant pleural mesothe-lioma. Ann Thorac Surg 54:941-946
8. Churg A, Colby TV, Cagle P et al (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183-1200
9. Churg A, Cagle PT, Roggli VL (2006) Separation of benign and malignant mesothelial proliferations. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 83-101
10. Stevens MW, Leong AS, Fazzalari NL et al (1992) Cytopathol-ogy of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 8:333-341
11. Whitaker D (2000) The cytology of malignant mesothelioma. Cytopathology 11:139-151
12. Churg A, Cagle PT, Roggli VL (2006) Cytology of the serosal surfaces. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 11-31
13. Cakir E, Demirag F, Aydin M et al (2009) Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol 37:4-10
14. Kimura N, Data K, Araya Y et al (2009) Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol 37:885-890
15. Kato Y, Tsuta K, Seki K et al (2007) Immunohistochemical detection of GLUT-1 can discriminate between reactive meso-thelium and malignant mesothelioma. Mod Pathol 20:215-220
16. Sato A, Torii I, Okamura Y et al (2010) Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 23: 1458-1466
17. Shen J, Pinkus GS, Deshpande V et al (2009) Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 131:516-523
18. Shi M, Fraire AE, Chu P et al (2011) Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 35: 878-882
19. van der Bij S, Schaake E, Koffijberg H et al (2011) Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 104:1325-1333
20. Cagle PT, Churg A (2005) Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 129:1421-1427
21. Husain AN, Colby TV, Ordonez NG et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133:1317-1331
22. Klebe S, Henderson DW (2011) Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 189: 169-193
23. Whitaker D, Henderson DW, Shilkin KB (1992) The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9:151-161
24. Henderson DW, Shilkin KB, Whitaker D (1998) Reactive mes-othelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110:397-404
25. Hammar SP, Henderson DW, Klebe S et al (2008) Neoplasms of the pleura. In: Tomashefski JFJ (ed) Dail and Hammar's pulmonary pathology, chap 43, vol 2, 3rd edn. Springer, New York, pp 558-734
26. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122-1128
27. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717
28. Kamei T (2010) Cytological diagnosis for mesothelioma. In: An abstract of the 10th international conference of the international mesothelioma interest group, Aug 31-Sept 3, 2010 Kyoto, Japan, p 36
29. Churg A, Cagle PT, Roggli VL (2006) Diffuse malignant tumors of the serosal membranes. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 33-82
30. Fetsch PA, Abati A (2001) Immunocytochemistry in effusion cytology: a contemporary review. Cancer 93:293-308
31. Pu RT, Pang Y, Michael CW (2008) Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immu-nostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 36:20-25
32. Bishop JA, Sharma R, Illei PB (2010) Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, and malignant mesothelioma. Hum Pathol 41:20-25
33. Khoor A, Whitsett JA, Stahlman MT et al (1999) Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30:695-700
34. Wolanski KD, Whitaker D, Shilkin KB et al (1998) The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82:583-590
35. Saad RS, Cho P, Liu YL (2005) The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 32:156-159
36. Attanoos RL, Griffin A, Gibbs AR (2003) The use of immuno-histochemistry in distinguishing reactive from neoplastic meso-thelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231-238
37. Ramael M, Lemmens G, Eerdekens C et al (1992) Immunore-activity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168:371-375
38. Hurlimann J (1994) Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 25:753-757
39. Davidson B, Nielsen S, Christensen J et al (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405-1412
40. Cury PM, Butcher DN, Corrin B et al (1999) The use of histo-logical and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189:251-257
41. King J, Thatcher N, Pickering C et al (2006) Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 49:561-568
42. Kumaki F, Kawai T, Churg A et al (2002) Expression of telo-merase reverse transcriptase (TERT) in malignant mesothelio-mas. Am J Surg Pathol 26:365-370
43. Xio S, Li D, Vijg J et al (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511-515
44. Prins JB, Williamson KA, Kamp MM et al (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649-653
45. Onofre FB, Onofre AS, Pomjanski N et al (2008) 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 114:204-215
46. Takeda M, Kasai T, Enomoto Y et al (2010) 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 60:395-399
47. Chung CT, Santos Gda C, Hwang DM et al (2010) FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630-634
48. Monaco SE, Shuai Y, Bansal M et al (2011) The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 135:619-627
49. Altomare DA, Menges CW, Xu J et al (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumori-genesis. PloS One 6:e18828
50. Sekido Y, Pass HI, Bader S et al (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227-1231
51. Bianchi AB, Mitsunaga SI, Cheng JQ et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854-10858
52. Baser ME (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27:297-306
53. McClatchey AI, Giovannini M (2005) Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev 19:2265-2277
54. Murakami H, Mizuno T, Taniguchi T et al (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873-883
55. Altomare DA, Vaslet CA, Skele KL et al (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65:8090-8095
56. Jensen DE, Proctor M, Marquis ST et al (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097-1112
57. Nishikawa H, Wu W, Koike A et al (2009) BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 69:111-119
58. Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-1413
59. Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668-672
60. Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022-1025
61. Yoshikawa Y, Sato A, Tsujimura T et al (2011) Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithe-lioid type of malignant mesothelioma cells. Int J Oncol 39:1365-1374
62. Taniguchi T, Karnan S, Fukui T et al (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98:438-446
63. Destro A, Ceresoli GL, Falleni M et al (2006) EGFR overex-pression in malignant pleural mesothelioma. An immunohisto-chemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207-215
64. Altomare DA, You H, Xiao GH et al (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Onco-gene 24:6080-6089
65. Suzuki Y, Murakami H, Kawaguchi K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2:181-188
66. Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. Oncol Rep 8:1375-1379
67. INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87:1870-1875
68. ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18:425-433
69. Thomas RK, Baker AC, Debiasi RM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351